Plixorafenib

DRUG3 trials

Sponsors

Fore Biotherapeutics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

BRAF V600E MutationCancer Harboring BRAF AlterationsHGGHealthy ParticipantsLGGSolid Tumors

Early Phase 1

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

RecruitingNCT06610682

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBRAF V600E Mutation

Start: 2025-04-07End: 2028-06-30Target: 24Updated: 2026-04-16

Phase 1

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

CompletedNCT06385119

Fore BiotherapeuticsHealthy Participants

Start: 2024-04-24End: 2025-01-07Updated: 2026-03-27

Phase 2

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

RecruitingNCT05503797

Fore BiotherapeuticsCancer Harboring BRAF Alterations, HGG, LGG +1

Start: 2023-02-21End: 2028-12-28Target: 254Updated: 2026-07-27

Related Papers

A trial to evaluate CSF ctDNA and safety of plixorafenib alone or with retifanlimab in patients with BRAF-altered glioma.

Journal of Clinical Oncology2026-05-28

Abstract CT273: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers

Cancer Research2026-04-17

FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers.

Journal of Clinical Oncology2025-05-281 citations

Trial in progress: Feasibility of CSF and plasma ctDNA in BRAF-altered glioma during treatment with plixorafenib.

Journal of Clinical Oncology2025-05-28

Abstract CT247: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers

Cancer Research2025-04-252 citations

TRLS-02. SAFETY AND EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394; PLX8394) IN CHILDREN AND ADULTS WITH RECURRENT, BRAF-ALTERED PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)

Neuro-Oncology2024-06-182 citations

CTNI-76. EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394) IN RECURRENT, PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST)

Neuro-Oncology2023-11-014 citations